KOREA WHO

Chun Jon Jong-sik is the CEO of CJ Bioscience.

He leads CJ Group's bio-business, focusing on new drug development and diagnostic services utilizing the human microbiome (microbial communities).

He aims to elevate the company to the global number one microbiome company by 2025, with goals of having 10 new drug candidates (pipeline) and two technology exports.

Born on February 20, 1967.

He graduated from the Department of Microbiology at Seoul National University and obtained a Ph.D. in Bacteriology from Newcastle University in the UK.

He worked as a researcher at the Marine Biotechnology Institute of the University of Maryland, USA, and as a senior researcher at the Korea Research Institute of Bioscience and Biotechnology, before being appointed as a professor in the Department of Biological Sciences at Seoul National University.

While serving as a professor, he founded ChunLab, a microbiome specialty company. After ChunLab was acquired by CJ Group and transformed into CJ Bioscience, he resigned from his professorship to focus on the business.

He founded the company believing that research on microorganisms alone had limitations in contributing to society and that various substances necessary for humanity could be discovered through microorganisms.

He is a scholar in the field of microbiology who has been selected as a Highly Cited Researcher (HCR) in the world's top 0.1% for five consecutive years.

He is interested in making microbiology-related information easily accessible to the general public through media appearances and writing.

#Keywords
#ChunJonJongSik #CJBioscience #microbiome #newdrugdevelopment #biotechnology #SeoulNationalUniversity #ChunLab #highlycitedresearcher #microbialresearch #biopharmaceuticals